Business Description
Newron Pharmaceuticals SpA
ISIN : IT0004147952
Total Employee Number:
27Description
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.76 | |||||
Equity-to-Asset | -0.28 | |||||
Debt-to-Equity | -3.43 | |||||
Debt-to-EBITDA | -4.91 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 2.13 | |||||
Beneish M-Score | -9.34 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 38.4 | |||||
3-Year EBITDA Growth Rate | 21 | |||||
3-Year EPS without NRI Growth Rate | 14 | |||||
3-Year Book Growth Rate | 12.5 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 100 | |||||
9-Day RSI | 100 | |||||
14-Day RSI | 100 | |||||
6-1 Month Momentum % | 113.68 | |||||
12-1 Month Momentum % | 113.68 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.76 | |||||
Quick Ratio | 0.76 | |||||
Cash Ratio | 0.58 | |||||
Days Sales Outstanding | 335.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.9 | |||||
Shareholder Yield % | 1.63 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -24.44 | |||||
Net Margin % | -69 | |||||
EBITDA Margin % | -40.51 | |||||
FCF Margin % | 167.83 | |||||
OCF Margin % | 168.08 | |||||
ROA % | -23.97 | |||||
ROIC % | -10.3 | |||||
3-Year ROIIC % | 25.75 | |||||
ROC (Joel Greenblatt) % | -44.52 | |||||
ROCE % | -46.04 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 17.52 | |||||
Price-to-Owner-Earnings | 8.01 | |||||
PS Ratio | 14.09 | |||||
Price-to-Free-Cash-Flow | 8.33 | |||||
Price-to-Operating-Cash-Flow | 8.32 | |||||
EV-to-EBIT | -36.63 | |||||
EV-to-Forward-EBIT | 16.26 | |||||
EV-to-EBITDA | -37.44 | |||||
EV-to-Forward-EBITDA | 4.74 | |||||
EV-to-Revenue | 15.17 | |||||
EV-to-Forward-Revenue | 22.71 | |||||
EV-to-FCF | 8.96 | |||||
Price-to-GF-Value | 0.98 | |||||
Price-to-Median-PS-Value | 1.07 | |||||
Earnings Yield (Greenblatt) % | -2.73 | |||||
FCF Yield % | 11.52 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:NWPHF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Newron Pharmaceuticals SpA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 22.187 | ||
| EPS (TTM) ($) | -0.773 | ||
| Beta | -2.7408 | ||
| 3-Year Sharpe Ratio | 0.89 | ||
| 3-Year Sortino Ratio | 7.55 | ||
| Volatility % | 113.68 | ||
| 14-Day RSI | 100 | ||
| 14-Day ATR ($) | 0.006622 | ||
| 20-Day SMA ($) | 20 | ||
| 12-1 Month Momentum % | 113.68 | ||
| 52-Week Range ($) | 9.36 - 20 | ||
| Shares Outstanding (Mil) | 20.81 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Newron Pharmaceuticals SpA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Newron Pharmaceuticals SpA Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Newron Pharmaceuticals SpA Frequently Asked Questions
What is Newron Pharmaceuticals SpA(NWPHF)'s stock price today?
The current price of NWPHF is $20.00. The 52 week high of NWPHF is $20.00 and 52 week low is $9.36.
When is next earnings date of Newron Pharmaceuticals SpA(NWPHF)?
The next earnings date of Newron Pharmaceuticals SpA(NWPHF) is .
Does Newron Pharmaceuticals SpA(NWPHF) pay dividends? If so, how much?
Newron Pharmaceuticals SpA(NWPHF) does not pay dividend.
Guru Commentaries on OTCPK:NWPHF
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Newron Pharmaceuticals SpA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers